• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Verve Therapeutics Inc.

    4/25/25 7:45:44 AM ET
    $VERV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VERV alert in real time by email
    DEFA14A 1 d933474ddefa14a.htm DEFA14A DEFA14A
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

     

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material under §240.14a-12

     

    Verve Therapeutics, Inc.

    (Name of Registrant as Specified in Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required.

     

    ☐

    Fee paid previously with preliminary materials.

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     
     


    LOGO

    P.O. BOX 8016, CARY, NC 27512-9903 Your vote Verve Therapeutics, Inc. Annual Meeting of Stockholders Thursday, June 5, 2025 9:00 AM, Eastern Time Annual Meeting to be held live via the Internet. You must register to attend the meeting online and/or participate prior to the deadline of June 4, 2025 at 5:00 pm ET. Please visit www.proxydocs.com/VERV for more details For a convenient way to view proxy materials, VOTE, and obtain directions to register for and attend the meeting, go to www.proxydocs.com/VERV To vote your proxy while visiting this site, you will need the 12 digit control number in the box below. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting. Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet. If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year’s meeting, you must make this request on or before May 26, 2025. Important Notice Regarding the Availability of Proxy Materials for the Stockholders Meeting To Be Held On June 5, 2025 For Stockholders of record as of April 11, 2025 Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report To order paper materials, use one of the following methods. Internet: www.investorelections.com/VERV Call: 1-866-648-8133 Email: [email protected] * If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material. Your control number SEE REVERSE FOR FULL AGENDA Have the 12 digit control number located in the box above available when you access the website and follow the instructions. Copyright © 2025 BetaNXT, Inc. or itsaffiliates.All


    LOGO

    Body Text;Verve Therapeutics, Inc. Annual Meeting of Stockholders THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR EACH OF THE NOMINEES IN PROPOSAL 1, AND FOR PROPOSALS 2 AND 3. Election of three Class I directors to our board of directors, each to serve until the 2028 annual meeting of stockholders. Lonnel Coats Jodie Morrison Krishna Yeshwant, M.D. Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025 Approval, on an advisory basis, of the compensation paid to our named executive officers. NOTE: To transact other business properly brought before the Annual Meeting or any adjournment or postponement thereof.

    Get the next $VERV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VERV

    DatePrice TargetRatingAnalyst
    4/15/2025Neutral → Overweight
    Cantor Fitzgerald
    4/8/2024$15.00Buy
    H.C. Wainwright
    4/13/2023$29.00Buy
    Canaccord Genuity
    2/1/2023$21.00Neutral
    Cantor Fitzgerald
    12/15/2022$13.00Sell
    Goldman
    10/6/2022$48.00Neutral
    Credit Suisse
    8/25/2022$32.00 → $56.00Hold → Buy
    Stifel
    6/17/2022$48.00Outperform
    BMO Capital Markets
    More analyst ratings

    $VERV
    Financials

    Live finance-specific insights

    See more
    • Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

      Single infusion of VERVE-102 led to dose-dependent decreases in blood PCSK9 and LDL-C, with mean reduction in LDL-C of 53% and a maximum reduction of 69% observed in the 0.6 mg/kg dose cohort VERVE-102 was well-tolerated with no treatment-related serious adverse events and no clinically significant changes in ALT or platelets observed at any dose level among 14 participants VERVE-102 utilizes a proprietary GalNAc-LNP which has demonstrated a potentially best-in-class safety profile In the second half of 2025, Verve expects to report final Heart-2 dose escalation data, dose the first patient in a Phase 2 clinical trial for VERVE-102, and receive a decision from Eli Lilly and Company for th

      4/14/25 7:00:00 AM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verve Therapeutics Announces Interim Data for VERVE-101 Demonstrating First Human Proof-of-Concept for In Vivo Base Editing with Dose-Dependent Reductions in LDL-C and Blood PCSK9 Protein in Patients with Heterozygous Familial Hypercholesterolemia

      LDL-C Reductions Up to 55% and Blood PCSK9 Protein Reductions Up to 84% Observed After a Single Infusion of VERVE-101 at Potentially Therapeutic Doses Safety Profile Supports Continued Development of VERVE-101 Enrollment Ongoing in the 0.45 mg/kg and 0.6 mg/kg Cohorts with Plans to Initiate Expansion Cohort in 2024 Company to Host Conference Call and Webcast Today at 6:30 p.m. ET BOSTON, Nov. 12, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced first human proof-of-concept data for in vivo base editing from the ongoing hear

      11/12/23 3:30:00 PM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERV
    Leadership Updates

    Live Leadership Updates

    See more
    • Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

      WELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors. Ms. Drapkin will assume the role of Audit Committee Chair, and Mr. Cumbo will assume the role of Compensation Committee Chair. "We are delighted to welcome Kim and Bo to our Board of Directors at Climb Bio," said Aoife Brennan, President and CEO of Climb Bio. "Kim and Bo each bring three decades of leadership experience in the biotechnology and pharmaceutical industry, offering invaluable perspective as we continue to build the company and advance our pipeline. Their insight

      4/1/25 7:00:00 AM ET
      $ABOS
      $CLYM
      $LENZ
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Verve Expands Leadership Team with Appointment of Frederick T. Fiedorek, M.D., as Chief Medical Officer

      BOSTON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the appointment of Frederick "Fred" T. Fiedorek, M.D., as chief medical officer (CMO). Andrew Bellinger, M.D., Ph.D., the current chief scientific officer (CSO) and CMO, will transition to the role of CSO. "We are excited by the continued expansion of the Verve team and the execution of a plan to become a multi-product clinical-stage company," said Sekar Kathiresan, M.D., co-founder and chief executive officer of Verve. "Our heart-1 clinical trial is well underway, wi

      9/18/23 6:30:00 AM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verve Therapeutics Appoints Experienced Biotechnology Executive, Alexander G. "Bo" Cumbo, to its Board of Directors

      CAMBRIDGE, Mass., June 13, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Alexander G. "Bo" Cumbo, chief executive officer and president of AavantiBio, Inc., has joined the company's board of directors. "Bo is a highly experienced industry executive with a well-established track record of leading pharmaceutical and life sciences companies through critical processes in drug development and commercial execution," said Sekar Kathiresan, M.D., co-founder and chief executive officer of Verve. "As we focus on continued execution of our regulatory

      6/13/22 6:30:00 AM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Verve Therapeutics upgraded by Cantor Fitzgerald

      Cantor Fitzgerald upgraded Verve Therapeutics from Neutral to Overweight

      4/15/25 8:57:58 AM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Verve Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Verve Therapeutics with a rating of Buy and set a new price target of $15.00

      4/8/24 8:03:41 AM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity initiated coverage on Verve Therapeutics with a new price target

      Canaccord Genuity initiated coverage of Verve Therapeutics with a rating of Buy and set a new price target of $29.00

      4/13/23 7:37:44 AM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Verve Therapeutics Inc.

      SC 13G - Verve Therapeutics, Inc. (0001840574) (Subject)

      11/18/24 5:23:52 PM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Verve Therapeutics Inc.

      SC 13G/A - Verve Therapeutics, Inc. (0001840574) (Subject)

      11/12/24 5:52:40 PM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Verve Therapeutics Inc.

      SC 13G/A - Verve Therapeutics, Inc. (0001840574) (Subject)

      11/4/24 1:52:43 PM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Ashe Andrew D. bought $475,760 worth of shares (76,000 units at $6.26), increasing direct ownership by 29% to 342,509 units (SEC Form 4)

      4 - Verve Therapeutics, Inc. (0001840574) (Issuer)

      5/15/24 5:30:07 PM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Yeshwant Krishna bought $18,000,000 worth of shares (1,800,000 units at $10.00) (SEC Form 4)

      4 - Verve Therapeutics, Inc. (0001840574) (Issuer)

      12/5/23 4:30:09 PM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2025 Financial Results

      Reported positive initial data from the Heart-2 Phase 1b clinical trial of VERVE-102 demonstrating dose-dependent decreases in blood LDL-C and PCSK9 Mean reduction in LDL-C of 53%, with a maximum reduction of 69%, observed after a single infusion of VERVE-102 in the 0.6 mg/kg dose cohort in the Heart-2 clinical trial Pulse-1 Phase 1b clinical trial of VERVE-201 targeting ANGPTL3 continues to progress with a program update expected in the second half of 2025 Cash, cash equivalents, and marketable securities of approximately $500 million; cash runway into mid-2027 BOSTON , May 14, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic med

      5/14/25 7:00:00 AM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

      BOSTON , May 02, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on April 30, 2025, the company granted equity awards to seven new employees, pursuant to the company's 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). The employees received stock options to purchase an aggregate of 134,860 shares of the company's common stock and an aggregate of 65,398 restricted stock units (RSUs). The options have an exercise price of $5.67 per share, which is equa

      5/2/25 4:05:00 PM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

      Single infusion of VERVE-102 led to dose-dependent decreases in blood PCSK9 and LDL-C, with mean reduction in LDL-C of 53% and a maximum reduction of 69% observed in the 0.6 mg/kg dose cohort VERVE-102 was well-tolerated with no treatment-related serious adverse events and no clinically significant changes in ALT or platelets observed at any dose level among 14 participants VERVE-102 utilizes a proprietary GalNAc-LNP which has demonstrated a potentially best-in-class safety profile In the second half of 2025, Verve expects to report final Heart-2 dose escalation data, dose the first patient in a Phase 2 clinical trial for VERVE-102, and receive a decision from Eli Lilly and Company for th

      4/14/25 7:00:00 AM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERV
    SEC Filings

    See more
    • SEC Form EFFECT filed by Verve Therapeutics Inc.

      EFFECT - Verve Therapeutics, Inc. (0001840574) (Filer)

      5/15/25 12:15:05 AM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Verve Therapeutics Inc.

      10-Q - Verve Therapeutics, Inc. (0001840574) (Filer)

      5/14/25 7:30:21 AM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verve Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Verve Therapeutics, Inc. (0001840574) (Filer)

      5/14/25 7:15:09 AM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VERV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Administrative Officer Nickerson Joan converted options into 9,315 shares and sold $11,525 worth of shares (2,777 units at $4.15), increasing direct ownership by 60% to 17,420 units (SEC Form 4)

      4 - Verve Therapeutics, Inc. (0001840574) (Issuer)

      4/3/25 5:00:17 PM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Ashe Andrew D. converted options into 9,000 shares and sold $11,126 worth of shares (2,681 units at $4.15), increasing direct ownership by 2% to 348,828 units (SEC Form 4)

      4 - Verve Therapeutics, Inc. (0001840574) (Issuer)

      4/3/25 5:00:14 PM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Kathiresan Sekar converted options into 33,000 shares and sold $40,761 worth of shares (9,822 units at $4.15), increasing direct ownership by 7% to 346,686 units (SEC Form 4)

      4 - Verve Therapeutics, Inc. (0001840574) (Issuer)

      4/3/25 5:00:19 PM ET
      $VERV
      Biotechnology: Pharmaceutical Preparations
      Health Care